---
title: "PHAT: VOQUEZNA drives GI market innovation with strong growth, clinical success, and extended exclusivity"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294354810.md"
description: "VOQUEZNA, a novel PCAB therapy, is addressing significant unmet needs in GI disorders, achieving strong commercial uptake and operating profitability in 2026. Clinical trials demonstrated superiority over PPIs, and the company projects continued revenue growth, extended exclusivity, and cash flow positivity in 2027.Original document: Phathom Pharmaceuticals, Inc. [PHAT] Slides Release — Jul. 30 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-30T11:21:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294354810.md)
  - [en](https://longbridge.com/en/news/294354810.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294354810.md)
generator: "portal-rs"
---

# PHAT: VOQUEZNA drives GI market innovation with strong growth, clinical success, and extended exclusivity

VOQUEZNA, a novel PCAB therapy, is addressing significant unmet needs in GI disorders, achieving strong commercial uptake and operating profitability in 2026. Clinical trials demonstrated superiority over PPIs, and the company projects continued revenue growth, extended exclusivity, and cash flow positivity in 2027.

Original document: Phathom Pharmaceuticals, Inc. \[PHAT\] Slides Release — Jul. 30 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [PHAT.US](https://longbridge.com/en/quote/PHAT.US.md)

## Related News & Research

- [Hennion & Walsh Asset Management Inc. Has $3.55 Million Stake in Phathom Pharmaceuticals, Inc. $PHAT](https://longbridge.com/en/news/295510829.md)
- [One Platform, Every Ailment: Hinge Health's Gamble](https://longbridge.com/en/news/296483875.md)
- [10:31 ETLiver Cirrhosis Market to Expand Significantly Through 2036, Driven by Emerging Therapies and Increasing Disease Burden | DelveInsight](https://longbridge.com/en/news/296802956.md)
- [Can Komzifti's Early Adoption Support Kura Oncology's Next Phase Of Growth?](https://longbridge.com/en/news/296928079.md)
- [EH: Revenues soared 203.5% QoQ, but regulatory caution in China clouds near-term outlook](https://longbridge.com/en/news/296894241.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**